Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 250

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 250
---
 provided by Longevity’s management team;                                              |

| 124 |

| ● | performed a discounted cash flow                                                     
 analysis layered onto the different Longevity three business units’ financial models 
 provided; and                                                                        |

| ● | performed public company comparable                                                                 
 analyses of similar companies to those of Longevity’s three business units that traded              
 on a major U.S. Stock Exchange, operated in the healthcare sector with different emphases           
 on three different sub-sectors including “soft tissue repair” for Aegeria, “retinal                 
 vein occlusion” for Reflow RVO, and “stroke care/recovery” for Aereva.                              
 These comparables were also selected on the basis that they were still in a “pre-commercialization” 
 phase in order to derive equity values;                                                             |

In conducting its review and arriving at its opinion, Newbridge did not independently verify any of the foregoing information and Newbridge assumed and relied upon such information being accurate and complete in all material respects, and Newbridge further relied upon the assurances of management of FutureTech that they are not aware of any facts that would make any of the information reviewed by Newbridge inaccurate, incomplete or misleading in any material respect. In addition, Newbridge has not assumed any responsibility for any independent valuation or appraisal of the assets or liabilities, including any ongoing litigation and administrative investigations, if any, of the Company, nor has Newbridge been furnished with any such valuation or appraisal. In addition, Newbridge has not assumed any obligation to conduct, nor has it conducted, any physical inspection of the properties or facilities of LBI.

The issuance of Newbridge’s opinion was approved by an authorized internal committee of Newbridge. Newbridge’s opinion is necessarily based on economic, market and other conditions as they exist and can be evaluated on, and the information made available to it on, the date thereof. Newbridge expressed no opinion as to the underlying valuation, future performance or long-term viability of FutureTech and its successors. Further, Newbridge expressed no opinion as to what the value of the shares of FutureTech Common Stock actually will be when the Business Combination is consummated or the prices at which shares of FutureTech Common Stock will trade at any time. It should be understood that, although subsequent developments may affect Newbridge’s opinion, Newbridge does not have any obligation to update, revise or reaffirm its opinion and has expressly disclaimed any responsibility to do so.

The following represents a brief summary of the material financial analyses reviewed by the FutureTech Board and performed by